News

lupus.bmj2d
PO.5.108 Combined model of renal histopathology and clinical parameters better predicts one-year renal outcomes in lupus nephritis: analysis of 334 kidney biopsies
Background/Purpose Diagnosis of Lupus Nephritis (LN) is currently based on laboratory tests and renal histopathology. The role of histopathological features in determining long term outcomes is ...
lupus.bmj1mon
Correction: Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?
Guillermo Ruiz-Irastorza, Diana Paredes-Ruiz, Fernando Arizpe et al. Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? Lupus Sci Med 2025;12:e001254. doi: ...
lupus.bmj1mon
LP-141 Delay to diagnosis of systemic lupus erythematosus and its impact on cumulative damage and mortality: data from a multiethnic Latin American cohort
Background Systemic lupus erythematosus (SLE) often mimics the symptoms of other diseases, and the interval between symptom onset and diagnosis remains long in these patients. The aim of this study is ...
lupus.bmj1mon
P51 First case of lupus: Bishop Eraclius of Liège, Belgium
Background Around 963 A.D., Bishop Eraclius (Liège, Belgium) wrote an affidavit stating, ‘I … was nearly taken to death by the disease called Lupus.’ On the seventh night of praying at Saint Martin’s ...
lupus.bmj1mon
P145 Circulating interferon-α levels are elevated during pregnancy in women with SLE who deliver infants that are small for gestational age, preterm and/or have low birth weight
Objectives Adverse pregnancy outcomes (APOs) are more common among women with SLE compared to the general population and the underlying immunopathological mechanisms are largely unknown. The type I ...
lupus.bmj3mon
LSO-092 Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: two randomised, double-blind phase 2 clinical trials
Background Two Phase 2 studies investigating once-daily cenerimod, a selective sphingosine 1-phosphate 1 receptor modulator, in adults with SLE were recently completed: CARE (NCT03742037) and ...
lupus.bmj3mon
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study
Background Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines (eg, Type 1 IFNs, IL-23, and IL-12) involved in lupus pathogenesis. Deucravacitinib is a first-in-class, oral, selective, ...
lupus.bmj4mon
O33 Longitudinal assessment of biomarkers in NOBILITY, a randomized, phase II clinical trial of obinutuzumab for treatment of proliferative lupus nephritis
Objective To investigate changes in peripheral B cells, B-cell subsets and biomarkers in NOBILITY. Methods In the randomized Phase II NOBILITY trial (NCT02550652), patients with lupus nephritis ...
lupus.bmj5mon
LSO-101 A spatially-resolved single cell resolution atlas of pediatric lupus nephritisuncovers complex interactions between stromal and infiltrating immune cells
Background The molecular and cellular heterogeneity of human Lupus Nephritis (LN) at the kidney tissue level makes it challenging to identify key disease drivers and therapeutic targets. Single-cell ...
lupus.bmj5mon
LP-060 Extracellular vesicular proteins in plasma from patients with cutaneous lupus correlate with disease activity
Background Cutaneous lupus erythematous (CLE) is amanifestation of systemic lupus erythematosus (SLE) that may have no systemic symptoms. SLE is known to affect a heterogeneous group of patients, and ...
lupus.bmj6mon
29 Lupus and the bones
Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...